Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

205.52 +0.04 (+0.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
22 23 Next >
News headline image
$1000 Invested In This Stock 15 Years Ago Would Be Worth $7,600 Today ↗
 
Via Benzinga
News headline image
Where Alnylam Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Alnylam Clocks ~50% Revenue Growth In Q1 On Solid Commercial Execution ↗
 
Via Benzinga
News headline image
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
How To Attend Alnylam Pharmaceuticals Q1 2023 Earnings Conference Call ↗
 
Via Benzinga
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today ↗
 
Via Benzinga
News headline image
A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Alnylam Issues 2022 Corporate Responsibility Report
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says ↗
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and its partner Regeneron Pharmaceuticals Inc (NASDAQ: REGN)  
Via Benzinga
News headline image
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Analyst Ratings for Alnylam Pharmaceuticals ↗
 
Via Benzinga
News headline image
Alnylam Pharmaceuticals's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Analyst Ratings for Alnylam Pharmaceuticals ↗
 
Via Benzinga
News headline image
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Why Legend Biotech Stock Is Having Its Best Month Yet
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high. 
Via MarketBeat
News headline image
3 Pharma Stocks That Could See a Surge in Demand in 2023 ↗
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead 
Via InvestorPlace
News headline image
Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward' ↗
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy... 
Via Benzinga
News headline image
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗
 
Via Benzinga
News headline image
3 Growth Stocks That Could Disrupt the Healthcare Industry ↗
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time. 
Via InvestorPlace
News headline image
Alnylam Announces Appointment of Peter Kellogg to Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Looking Into Alnylam Pharmaceuticals's Recent Short Interest ↗
Alnylam Pharmaceuticals's (NASDAQ:ALNY) short percent of float has fallen 5.3% since its last report. The company recently reported that it has 5.10 million shares sold short, which is 4.82% of all... 
Via Benzinga
News headline image
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗
 
Via Benzinga
News headline image
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.